VistaGen Therapeutics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, VistaGen Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 4 completed top decile by trial count

VistaGen Therapeutics: 9 sponsored US clinical trials, 2 recruiting.

VistaGen Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Social Anxiety Disorder, with 2 trials.

Top-decile sponsor footprint

VistaGen Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

NCT06809179
RECRUITING Phase 3

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
ACTIVE NOT RECRUITING Phase 3

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

NCT06358651
COMPLETED Phase 2

PH94B in the Treatment of Adjustment Disorder With Anxiety

NCT04404192
TERMINATED Phase 3

Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

NCT05030350
TERMINATED Phase 3

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

NCT05011396
COMPLETED Phase 3

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

NCT04754802
COMPLETED Phase 2

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

NCT03078322
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

NCT01483846

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 5

Therapeutic Areas

Social Anxiety Disorder 2
Adjustment Disorder With Anxious Mood 1
Social Anxiety Disorder (SAD) 1

What is open in the VistaGen Therapeutics pipeline

2 recruiting of 9 indexed (22% open); 4 completed (44%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Social Anxiety Disorder (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

VistaGen Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

VistaGen Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share VistaGen Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
VistaGen Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

VistaGen Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this VistaGen Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of VistaGen Therapeutics or any single study.

  • 2 of VistaGen Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Social Anxiety Disorder is the condition VistaGen Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Social Anxiety Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

VistaGen Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.